{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:54:06Z","timestamp":1793357646562,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100011879","name":"California Public Utilities Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011879","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1K08DK114563-01"],"award-info":[{"award-number":["1K08DK114563-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","gastrojournal.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1053\/j.gastro.2020.08.063","type":"journal-article","created":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T19:25:58Z","timestamp":1602962758000},"page":"1384-1393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":284,"title":["AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review"],"prefix":"10.1053","volume":"160","author":[{"given":"Michael","family":"Dougan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Rubio-Tapia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph K.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2020.08.063_bib1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","article-title":"Adverse events following cancer immunotherapy: obstacles and opportunities","volume":"40","author":"Pauken","year":"2019","journal-title":"Trends Immunol"},{"key":"10.1053\/j.gastro.2020.08.063_bib2","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1344805","article-title":"Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis","volume":"6","author":"Wang","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1053\/j.gastro.2020.08.063_bib3","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.gastro.2020.08.063_bib4","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4","volume":"24","author":"Beck","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.gastro.2020.08.063_bib5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/his.13963","article-title":"Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies","volume":"76","author":"Zhang","year":"2020","journal-title":"Histopathology"},{"key":"10.1053\/j.gastro.2020.08.063_bib6","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1093\/annonc\/mdx403","article-title":"Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies","volume":"28","author":"Collins","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1053\/j.gastro.2020.08.063_bib7","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/hep4.1465","article-title":"Biologic and checkpoint inhibitor-induced liver injury: a systematic literature review","volume":"4","author":"Shah","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1053\/j.gastro.2020.08.063_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40425-019-0502-7","article-title":"Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1053\/j.gastro.2020.08.063_bib9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s40425-019-0604-2","article-title":"Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1053\/j.gastro.2020.08.063_bib10","series-title":"Common Terminology Criteria for Adverse Events","year":"2017"},{"key":"10.1053\/j.gastro.2020.08.063_bib11","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s40425-019-0756-0","article-title":"Budesonide treatment for microscopic colitis from immune checkpoint inhibitors","volume":"7","author":"Hughes","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1053\/j.gastro.2020.08.063_bib12","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1158\/2326-6066.CIR-17-0659","article-title":"Clinical significance of pancreatic atrophy induced by immune-checkpoint inhibitors: a case-control study","volume":"6","author":"Eshet","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1053\/j.gastro.2020.08.063_bib13","article-title":"Immune checkpoint inhibitor-associated celiac disease","volume":"8","author":"Badran","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1053\/j.gastro.2020.08.063_bib14","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/ibd\/izy104","article-title":"Endoscopic and histologic features of immune checkpoint inhibitor-related colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1053\/j.gastro.2020.08.063_bib15","article-title":"Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis","volume":"8","author":"Mooradian","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1053\/j.gastro.2020.08.063_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-018-0411-1","article-title":"Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1053\/j.gastro.2020.08.063_bib17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/ecco-jcc\/jjv227","article-title":"Cancer Immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease","volume":"10","author":"Marthey","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2020.08.063_bib18","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/2326-6066.CIR-16-0302","article-title":"Diagnostic comparison of CT scans and colonoscopy for immune-related colitis in ipilimumab-treated advanced melanoma patients","volume":"5","author":"Garcia-Neuer","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1053\/j.gastro.2020.08.063_bib19","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.gastro.2020.08.063_bib20","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1053\/j.gastro.2020.08.063_bib21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1053\/j.gastro.2020.08.063_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40425-018-0412-0","article-title":"Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis","volume":"6","author":"Johnson","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1053\/j.gastro.2020.08.063_bib23","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s40425-018-0461-4","article-title":"Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1053\/j.gastro.2020.08.063_bib24","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-19-3322","article-title":"Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1-treated patients in the Dutch Melanoma Treatment Registry","volume":"26","author":"Verheijden","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2020.08.063_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40425-019-0532-1","article-title":"Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab","volume":"7","author":"Zhang","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1053\/j.gastro.2020.08.063_bib26","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/s41591-018-0238-9","article-title":"Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Nat Med"},{"key":"10.1053\/j.gastro.2020.08.063_bib27","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A\u00a0randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2020.08.063_bib28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40425-019-0577-1","article-title":"Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1053\/j.gastro.2020.08.063_bib29","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.19.00320","article-title":"Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis","volume":"37","author":"Abu-Sbeih","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.gastro.2020.08.063_bib30","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s40425-019-0711-0","article-title":"Concurrent therapy with immune checkpoint inhibitors and TNFalpha blockade in patients with gastrointestinal immune-related adverse events","volume":"7","author":"Badran","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1053\/j.gastro.2020.08.063_bib31","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.19.01674","article-title":"Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease","volume":"38","author":"Abu-Sbeih","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.gastro.2020.08.063_bib32","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1634\/theoncologist.2018-0174","article-title":"Diagnosis and management of hepatitis in patients on checkpoint blockade","volume":"23","author":"Reynolds","year":"2018","journal-title":"Oncologist"},{"key":"10.1053\/j.gastro.2020.08.063_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919830826","article-title":"Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials","volume":"11","author":"Pelster","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"10.1053\/j.gastro.2020.08.063_bib34","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/PAS.0000000000000759","article-title":"Fibrin ring granulomas in checkpoint inhibitor-induced hepatitis","volume":"41","author":"Everett","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1053\/j.gastro.2020.08.063_bib35","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","article-title":"Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases","volume":"39","author":"Johncilla","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1053\/j.gastro.2020.08.063_bib36","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","article-title":"Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury","volume":"31","author":"Zen","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1053\/j.gastro.2020.08.063_bib37","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejca.2017.05.018","article-title":"Severe hepatitis under combined immunotherapy: resolution under corticosteroids plus anti-thymocyte immunoglobulins","volume":"81","author":"Spankuch","year":"2017","journal-title":"Eur J Cancer"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508520352823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508520352823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T19:52:13Z","timestamp":1721332333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508520352823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0016508520352823"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2020.08.063","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2020.08.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the AGA Institute","name":"copyright","label":"Copyright"}]}}